PD-L1-positive recurrent and metastatic cervical cancer responsive to
first-line Sintilimab with chemotherapy plus Bevacizumab treatment: a
Cervical cancer is the most common malignant tumor of the female
reproductive system. Its incidence rate ranks first among that of female
malignant tumors in China and has steadily increased in recent years
[Juanjuan Jin et al., 2021].